Telemedicine Self-examination of Speech and Memory for Rapid Detection of Cognitive Impairments Using Machine Learning Methods

Early cognitive disorders diagnosis is becoming increasingly important due to population aging. The most common causes include Alzheimer's disease and frontotemporal dementia. These diseases are also manifested by changes in speech. NLP allows us to identify and classify these changes. The project aims to develop a web application for self-assessment and automated detection of cognitive disorders from speech. The application will have a form of a dialogue system using machine learning methods. The novelty of this approach is the possibility of an efficient self-assessment of a wide spectrum of the Czech population from their homes and an automated evaluation of test results. Early detection can be followed by a more detailed diagnosis and adequate treatment.

Study Overview

• Status: Enrolling by invitation
• Conditions: Dementia; Mild Cognitive Impairment (MCI); Frontotemporal Degeneration (FTD); Alzheimer Disease (AD); Mild Cognitive Impairment (MCI) Amnestic
• Intervention / Treatment: Diagnostic test: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); Diagnostic test: the Mississippi Aphasia Screening Test; Diagnostic test: Amnesia Light and Brief Assessment (ALBA); Diagnostic test: The Picture naming and immediate recall test (PICNIR); Diagnostic test: Geriatric Depression Scale (GDS-15); Diagnostic test: The Beck Anxiety Inventory (BAI); Diagnostic test: Digitial Diagnostics of Dementia (DDD)

• Study Type: Interventional
• Enrollment (Estimated): 500
• Phase: Not Applicable

Contacts and Locations

Study Locations

• Czechia
  • Pilsen, Czechia, 306 14
    • Západočeská univerzita v Plzni / Fakulta aplikovaných věd
  • Prague, Czechia, 100 00
    • Faculty Hospital Královské Vinohrady
  • Prague, Czechia
    • Fyzikální ústav AV ČR, v. v. i.

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria for the group of healthy participants:

• age over 45 years
• Czech as the native language
• must meet the criteria in a questionnaire with questions focused on a history of brain injury or psychiatric history or medication use
• must achieve normal scores on questionnaires assessing mood

Inclusion Criteria for the group of patients:

- be diagnosed with mild neurocognitive impairment (MCI) or neurocognitive disorder (dementia) according to the international DSM-5 criteria

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: Non-Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Group of patients with neurocognitive disorder; The experimental group consists of patients with Mild Cognitive Impariment (MCI) and dementia.	Diagnostic test: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); A brief individually administered battery to measure cognitive decline or improvement across five domains in ages 12 to 89 years 11 months.; Diagnostic test: the Mississippi Aphasia Screening Test; he Mississippi Aphasia Screening Test (MAST) was developed as a brief, repeatable screening measure for individuals with severely impaired communication/language skills.; Diagnostic test: Amnesia Light and Brief Assessment (ALBA); Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).; Diagnostic test: The Picture naming and immediate recall test (PICNIR); Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).; Diagnostic test: Geriatric Depression Scale (GDS-15); The Geriatric Depression Scale (GDS-15), used to screen for depression in adults aged 55 and older, consists of 15 items that assess mental health based on feelings over the past week.; Diagnostic test: The Beck Anxiety Inventory (BAI); A formative assessment and rating scale of anxiety.; Diagnostic test: Digitial Diagnostics of Dementia (DDD); Our experimental screening battery developed for this study.
Active Comparator: Healthy elderly participants; The control group consists of cognitively healthy elderly participants.	Diagnostic test: The Repeatable Battery for the Assessment of Neuropsychological Status (RBANS); A brief individually administered battery to measure cognitive decline or improvement across five domains in ages 12 to 89 years 11 months.; Diagnostic test: the Mississippi Aphasia Screening Test; he Mississippi Aphasia Screening Test (MAST) was developed as a brief, repeatable screening measure for individuals with severely impaired communication/language skills.; Diagnostic test: Amnesia Light and Brief Assessment (ALBA); Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).; Diagnostic test: The Picture naming and immediate recall test (PICNIR); Very brief test used to measure deficits of more cognitive functions (short-term, episodic, semantic amnesia, sensory and motor aphasia, apraxia, psychomotor speed).; Diagnostic test: Geriatric Depression Scale (GDS-15); The Geriatric Depression Scale (GDS-15), used to screen for depression in adults aged 55 and older, consists of 15 items that assess mental health based on feelings over the past week.; Diagnostic test: The Beck Anxiety Inventory (BAI); A formative assessment and rating scale of anxiety.; Diagnostic test: Digitial Diagnostics of Dementia (DDD); Our experimental screening battery developed for this study.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
The difference in results between groups of patients with cognitive impairment and healthy individuals in individual parts of our experimental neuropsychological battery Diagnostic Test: Digitial Diagnostics of Dementia (DDD)	Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with RBANS	Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with MAST	Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with ALBA	Through study completion, an average of 2 years
Correlation of the results of our experimental battery (DDD) with POBAV	Through study completion, an average of 2 years

Collaborators and Investigators

• Sponsor: Faculty Hospital Kralovske Vinohrady
• Investigators: Study Chair: Luboš Šmídl, Ing. Ph.D., Západočeská univerzita v Plzni / Fakulta aplikovaných věd; Principal Investigator: Jan Švec, Ing. Ph.D., Západočeská univerzita v Plzni / Fakulta aplikovaných věd; Principal Investigator: Filip Polák, Ing., Západočeská univerzita v Plzni / Fakulta aplikovaných věd; Study Director: Aleš Bartoš, prof. MUDr. Ph.D., Fakultni nemocnice Kralovske Vinohrady; Study Director: Martin Víta, Mgr. Ph.D., Fyzikální ústav AV ČR, v. v. i.; Principal Investigator: Marie Kompasová, Mgr., Univerzita Karlova, Fakultní nemocnice Královské Vinohrady; Principal Investigator: Michaela Zapletalová, Mgr., Univerzita Palackého, Fakultní nemocnice Královské Vinohrady

Study record dates

Study Major Dates

• Study Start (Actual): September 1, 2023
• Primary Completion (Actual): December 31, 2025
• Study Completion (Estimated): August 31, 2026

Study Registration Dates

• First Submitted: December 16, 2025
• First Submitted That Met QC Criteria: April 27, 2026
• First Posted (Actual): April 30, 2026

Study Record Updates

• Last Update Posted (Actual): April 30, 2026
• Last Update Submitted That Met QC Criteria: April 27, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: dementia; cognition; screening; digital diagnostics; Mild Cognitive Impairment (MCI)
• Additional Relevant MeSH Terms: Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Mental Disorders; Neurocognitive Disorders; Cognition Disorders; Tauopathies; Neurodegenerative Diseases; Cognitive Dysfunction; Alzheimer Disease; Dementia
• Other Study ID Numbers: TQ01000332 (Other Grant/Funding Number: Technology Agency of the Czech Republic)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No